Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 9,945 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single-arm Clear all

Conditions: HIV-1
Interventions: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 16
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more

Conditions: Other Biomechanical Lesions of Upper Extremity
Interventions: Local anesthetic block [0.35% marcaine], Braun DIG-R-C Stimuplex Blockade Monitor System; Procedure · Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 21 Years to 89 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: SCI - Spinal Cord Injury, SCI, Spinal Cord Injury
Interventions: Human allogeneic, culture expanded, UC-MSC; Drug
Lead sponsor: Cell Therapy LLC; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dengue
Interventions: TetraVax-DV-TV005, rDEN3Δ30, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Pancreatic Cancer
Interventions: cisplatin, docetaxel, gemcitabine hydrochloride, irinotecan hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 75
States / cities: Anniston, Alabama • La Jolla, California • San Diego, California + 55 more

Conditions: HIV Infections With Multi Drug Resistant Virus
Interventions: Fostemsavir; Drug
Lead sponsor: PENTA Foundation; Network
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant; Drug · Procedure
Lead sponsor: Paul Richardson, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more

Conditions: Workplace Migraine Treatment
Interventions: Triptan, Treximet 85Mg-500Mg Tablet; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Kidney Transplant; Complications, Obesity
Interventions: Education regarding Weight loss, Lifestyle tools for weight loss, Blood draw; Behavioral · Biological
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Sleep, Mood, Caffeine Withdrawal, Anxiety, Productivity
Interventions: Clevr Sleeptime, Clevr Matcha, Clevr Chai; Other
Lead sponsor: Clevr Blends; Industry
Eligibility: 28 Years to 42 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Stress Urinary Incontinence (SUI)
Interventions: pessary handle; Device
Lead sponsor: Resilia Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Denosumab; Drug
Lead sponsor: Samsung Bioepis Co., Ltd.; Industry
Eligibility: 28 Years to 55 Years · Male only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Critical Limb Ischemia
Interventions: ASCT01 (Autologous Stem Cell Transplantation); Biological
Lead sponsor: Lifecells, LLC.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: North Kansas City, Missouri

Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib; Other · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 12
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more

Conditions: Heart Failure, Methamphetamine Use Disorder
Interventions: MUD Management (contingency management +/- adjunctive MUD pharmacotherapy), HF GDMT management; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Insomnia, Cardiovascular Risk Factor
Interventions: Cognitive-Behavior Therapy for Insomnia (CBT-I); Behavioral
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pruritus
Interventions: Dupilumab 300Mg Solution for Injection; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Ovarian Cancer
Interventions: ON 01910.Na; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions: RBN-2397; Drug
Lead sponsor: Ribon Therapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Newark, Delaware • Newnan, Georgia • Baton Rouge, Louisiana + 1 more

Conditions: Cystic Fibrosis
Interventions: micro Sweat Test Patch (mSTP), Sweat Testing using SOC; Device · Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 2 Weeks to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: Isosulfan blue, Axillary Lymph Node Dissection, Surgery, Sentinel Lymph Node Biopsy, Thoracoscopic Surgery, Technetium Tc 99m Sulfur Colloid; Drug · Procedure · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions
Interventions: DETOUR System; Device
Lead sponsor: Endologix; Industry
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 10
States / cities: Salinas, California • Storrs, Connecticut • Washington D.C., District of Columbia + 7 more

Conditions: Bladder Cancer
Interventions: BCG delivery at home; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 390
States / cities: Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 290 more

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

Nerve Stimulator for Patients With Upper Extremity Disease, Vascular or Orthopedic Surgery

NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCI

Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?

Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program

A Single-Arm, Virtual Clinical Trial to Evaluate the Effects of a Sleep Supporting Beverage and Two Coffee Substitute Products

A Study of Two Versions of the Uresta Pessary Handle for Women With Stress Urinary Incontinence

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects

Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Methamphetamine Use Disorder Support in Heart Failure Pilot Study

Integrative Cardiac Health Project Cognitive-Behavior Therapy for Insomnia

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer